High farnesoid X receptor expression predicts favorable clinical outcomes in PD-L1low/negative non-small cell lung cancer patients receiving anti-PD-1-based chemo-immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Oncology"
DOI: 10.3892/ijo.2022.5330
Abstract: Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-directed immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). However, predictive biomarkers are still lacking, particularly in identifying PD-L1low/negative patients who will benefit from immunotherapy. It… read more here.
Keywords: l1low negative; immunotherapy; based chemo; expression ... See more keywords